CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 102 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2018. The put-call ratio across all filers is 2.89 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $21,000 | -56.2% | 105,800 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $48,000 | -9.4% | 105,800 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $53,000 | -78.5% | 105,800 | 0.0% | 0.00% | -80.0% |
| Q1 2018 | $247,000 | -17.7% | 105,800 | 0.0% | 0.01% | -16.7% |
| Q4 2017 | $300,000 | -1.0% | 105,800 | 0.0% | 0.01% | +9.1% |
| Q3 2017 | $303,000 | +16.1% | 105,800 | 0.0% | 0.01% | +10.0% |
| Q2 2017 | $261,000 | -31.7% | 105,800 | 0.0% | 0.01% | -33.3% |
| Q1 2017 | $382,000 | +1.9% | 105,800 | 0.0% | 0.02% | -6.2% |
| Q4 2016 | $375,000 | -12.2% | 105,800 | 0.0% | 0.02% | 0.0% |
| Q3 2016 | $427,000 | -8.0% | 105,800 | 0.0% | 0.02% | -15.8% |
| Q2 2016 | $464,000 | +16.0% | 105,800 | 0.0% | 0.02% | +11.8% |
| Q1 2016 | $400,000 | -75.9% | 105,800 | 0.0% | 0.02% | -71.7% |
| Q4 2015 | $1,659,000 | -53.5% | 105,800 | -68.7% | 0.06% | -53.1% |
| Q3 2015 | $3,567,000 | -72.9% | 338,400 | -66.7% | 0.13% | -79.3% |
| Q3 2014 | $13,178,000 | – | 1,016,800 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |